Viewing Study NCT05856695


Ignite Creation Date: 2025-12-24 @ 2:17 PM
Ignite Modification Date: 2026-02-21 @ 6:45 PM
Study NCT ID: NCT05856695
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-24
First Post: 2023-05-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module